These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 19646431)
1. Enhancing prostate cancer cryotherapy using tumour necrosis factor related apoptosis-inducing ligand (TRAIL) sensitisation in an in vitro cryotherapy model. Ismail M; Morgan R; Harrington K; Davies J; Pandha H Cryobiology; 2009 Oct; 59(2):207-13. PubMed ID: 19646431 [TBL] [Abstract][Full Text] [Related]
2. Targeted induction of apoptosis via TRAIL and cryoablation: a novel strategy for the treatment of prostate cancer. Clarke DM; Robilotto AT; VanBuskirk RG; Baust JG; Gage AA; Baust JM Prostate Cancer Prostatic Dis; 2007; 10(2):175-84. PubMed ID: 17297503 [TBL] [Abstract][Full Text] [Related]
3. Chemo-cryo combination therapy: an adjunctive model for the treatment of prostate cancer. Clarke DM; Baust JM; Van Buskirk RG; Baust JG Cryobiology; 2001 Jun; 42(4):274-85. PubMed ID: 11748936 [TBL] [Abstract][Full Text] [Related]
4. Low-dose 12-O-tetradecanoylphorbol-13-acetate enhances tumor necrosis factor related apoptosis-inducing ligand induced apoptosis in prostate cancer cells. Zhang X; Li W; Olumi AF Clin Cancer Res; 2007 Dec; 13(23):7181-90. PubMed ID: 18056199 [TBL] [Abstract][Full Text] [Related]
5. Anti-gout agent allopurinol exerts cytotoxicity to human hormone-refractory prostate cancer cells in combination with tumor necrosis factor-related apoptosis-inducing ligand. Yasuda T; Yoshida T; Goda AE; Horinaka M; Yano K; Shiraishi T; Wakada M; Mizutani Y; Miki T; Sakai T Mol Cancer Res; 2008 Dec; 6(12):1852-60. PubMed ID: 19074830 [TBL] [Abstract][Full Text] [Related]
6. Human agonistic antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 induces cytotoxicity and apoptosis in prostate cancer and bladder cancer cells. Shimada O; Wu X; Jin X; Nouh MA; Fiscella M; Albert V; Matsuda T; Kakehi Y Urology; 2007 Feb; 69(2):395-401. PubMed ID: 17320696 [TBL] [Abstract][Full Text] [Related]
7. Is TRAIL the holy grail of cancer therapy? Newsom-Davis T; Prieske S; Walczak H Apoptosis; 2009 Apr; 14(4):607-23. PubMed ID: 19194800 [TBL] [Abstract][Full Text] [Related]
8. Cytotoxic effects of camptothecin and cisplatin combined with tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) in a model of primary culture of non-small cell lung cancer. Frese S; Schüller A; Frese-Schaper M; Gugger M; Schmid RA Anticancer Res; 2009 Aug; 29(8):2905-11. PubMed ID: 19661294 [TBL] [Abstract][Full Text] [Related]
9. Cryosurgery--a putative approach to molecular-based optimization. Baust JG; Gage AA; Clarke D; Baust JM; Van Buskirk R Cryobiology; 2004 Apr; 48(2):190-204. PubMed ID: 15094094 [TBL] [Abstract][Full Text] [Related]
10. Cryosurgical technique: assessment of the fundamental variables using human prostate cancer model systems. Klossner DP; Robilotto AT; Clarke DM; VanBuskirk RG; Baust JM; Gage AA; Baust JG Cryobiology; 2007 Dec; 55(3):189-99. PubMed ID: 17888898 [TBL] [Abstract][Full Text] [Related]
11. Susceptibility of the C2 canine mastocytoma cell line to the effects of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Elders RC; Baines SJ; Catchpole B Vet Immunol Immunopathol; 2009 Jul; 130(1-2):11-6. PubMed ID: 19185923 [TBL] [Abstract][Full Text] [Related]
12. TRAIL as a target in anti-cancer therapy. Wu GS Cancer Lett; 2009 Nov; 285(1):1-5. PubMed ID: 19299078 [TBL] [Abstract][Full Text] [Related]
13. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) for treatment of prostate cancer: first results and review of the literature. Van Ophoven A; Ng CP; Patel B; Bonavida B; Belldegrun A Prostate Cancer Prostatic Dis; 1999 Dec; 2(5/6):227-233. PubMed ID: 12497168 [TBL] [Abstract][Full Text] [Related]
14. Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells. Yang B; Wu X; Mao Y; Bao W; Gao L; Zhou P; Xie R; Zhou L; Zhu J Neurosurgery; 2009 Sep; 65(3):610-24; discussion 624. PubMed ID: 19687708 [TBL] [Abstract][Full Text] [Related]
15. Overcoming resistance to trail-induced apoptosis in prostate cancer by regulation of c-FLIP. Zhang X; Li W; Olumi AF Methods Enzymol; 2008; 446():333-49. PubMed ID: 18603132 [TBL] [Abstract][Full Text] [Related]
16. Concomitant use of Ad5/35 chimeric oncolytic adenovirus with TRAIL gene and taxol produces synergistic cytotoxicity in gastric cancer cells. Chen L; Chen D; Gong M; Na M; Li L; Wu H; Jiang L; Qian Y; Fang G; Xue X Cancer Lett; 2009 Nov; 284(2):141-8. PubMed ID: 19447545 [TBL] [Abstract][Full Text] [Related]
17. Effect of UV irradiation on colorectal cancer cells with acquired TRAIL resistance. Kim SC; Park SS; Lee YJ J Cell Biochem; 2008 Jul; 104(4):1172-80. PubMed ID: 18247342 [TBL] [Abstract][Full Text] [Related]
18. Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced chemokine release in both TRAIL-resistant and TRAIL-sensitive cells via nuclear factor kappa B. Tang W; Wang W; Zhang Y; Liu S; Liu Y; Zheng D FEBS J; 2009 Jan; 276(2):581-93. PubMed ID: 19120450 [TBL] [Abstract][Full Text] [Related]
19. Differential expression of TRAIL and its receptors in benign and malignant prostate tissues. Sanlioglu AD; Koksal IT; Ciftcioglu A; Baykara M; Luleci G; Sanlioglu S J Urol; 2007 Jan; 177(1):359-64. PubMed ID: 17162091 [TBL] [Abstract][Full Text] [Related]
20. The effect of TRAIL molecule on cell viability in in vitro beta cell culture. Tekmen I; Ozyurt D; Pekçetin C; Buldan Z Acta Diabetol; 2007 Jun; 44(2):60-4. PubMed ID: 17530468 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]